This site is intended for Healthcare Professionals outside the US

Starting therapy with JAKAVI

Recommended starting dose of JAKAVI is based on baseline platelet count1

Recommended starting dose by platelet count1

aThere is limited information to recommend a starting dose for these patients.
The maximum recommended starting dose is 5 mg twice daily and the patients should be titrated cautiously. Tablets shown are not actual size.

Important considerations for starting therapy with JAKAVI1

  • JAKAVI is taken orally, with or without food
  • A complete blood cell count, including a white blood cell count differential, must be performed before initiating therapy with JAKAVI
    • Complete blood cell counts should be monitored every 2 to 4 weeks until doses are stabilised, and then as clinically indicated
  • The starting dose should not be increased during the first 4 weeks of treatment
    • After 4 weeks, dosing should not be increased more frequently than at 2-week intervals
  • Maximum dose of JAKAVI: 25 mg twice daily
  • Range of tablet strengths are available: 5-mg, 10-mg, 15-mg, and 20-mg tablets

Next: Dose optimisation with JAKAVI

Reference:

  1. JAKAVI® (ruxolitinib) tablets: EU Summary of Product Characteristics. Novartis; May 2017.